Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452027 | 0.89 | MAPT (0.62) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL23452022 | 0.88 | IKBKB (0.63) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL23452155 | 0.88 | MAPT (0.61) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL7057270 | 0.87 | MAPT (0.76) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL17226314 | 0.87 | PTPN1 (0.68) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL2158351 | 0.87 | MAPT (0.71) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL7057264 | 0.87 | MAPT (0.80) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL5368759 | 0.87 | MAPT (1.00) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL23452054 | 0.86 | KDM4E (0.61) | MAPTKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL2157551 | 0.85 | KDM4E (0.69) | MAPTKDM4EALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306103-B2 | Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY | 2022-04-19 | — | — | US | disclosed |
| US-11306103-B2 | Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY | 2022-04-19 | — | — | US | disclosed |
| US-20210171539-A1 | NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2021-06-10 | — | — | US | disclosed |
| US-20210171539-A1 | NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2021-06-10 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | disclosed |
| CN-101624391-A | Thiophene derivatives as antiviral agents for flavivirus infection | VIROCHEM PHARMA INC | 2010-01-13 | — | — | CN | disclosed |
| EP-1401825-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | VIROCHEM PHARMA INC (CA) | 2009-08-05 | — | — | EP | disclosed |
| CN-100509797-C | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2009-07-08 | — | — | CN | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
| CN-1602308-A | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2005-03-30 | — | — | CN | disclosed |
| US-20040116509-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2004-06-17 | — | — | US | disclosed |
| EP-1401825-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | Shire Biochem Inc. (CA) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002100851-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | MAPT 1458/4885KDM4E 3220/4885ALDH1A1 684/4885 |
| US-20210171539-A1 | NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | BRD4, BRPF3, AFF4 | MAPT 2916/4885KDM4E 125/4885ALDH1A1 908/4885 |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | MAPT 1458/4885KDM4E 3220/4885ALDH1A1 684/4885 |
| US-11306103-B2 | Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof | BRD4, BRPF3, AFF4 | MAPT 2983/4885KDM4E 159/4885ALDH1A1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.